KLRD1 and plasma cell myeloma: Their contributions have been demonstrated by performing blocking experiments upon NK cell cytokine stimulation (32, 38, 39), which is of particular importance since anti-myeloma drugs are known to increase activating or decrease inhibitory NK cell receptor ligands on myeloma cells (40–42).